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Apoptosis is now recognized as a predominantmechanism by which b cells are destroyed inboth type 1 and type 2 diabetes (1). Pro- andantiapoptotic members of the Bcl-2 family are
central regulators involved in b-cell fate decision between
life and death in response to physiological insults. The
intricate interplay and balance between members of this
family regulate apoptosis by controlling mitochondrial cell
death signaling, the so-called intrinsic pathway (2). The
Bcl-2 family is divided into three subgroups as follows: 1)
the antiapoptotic Bcl-2–like proteins (Bcl-2, Bcl-xL, Bcl-W,
Mcl-1, and A1/Bﬂ1) that possess four independent and
highly conserved Bcl-2 homology (BH) domains (BH-1 to
-4); 2) the proapoptotic Bax-like proteins (Bax, Bak, and
Bok/Mtd), which also harbor the four BH domains; and 3)
proapoptotic members typiﬁed by a single BH-3 domain
(Bid, Bim/Bod, Bad, Bmf, Bik/Nbk, Blk, NoxA, Puma/Bbc3,
and Hrk/DP5). Members of this last subgroup initiate the
apoptotic-signaling cascade by interacting with anti-
apoptotic members (3). In addition, intracellular calcium
activity ([Ca2+]i) is an important second messenger that
initiates the apoptotic program (4) as well as being es-
sential in metabolism secretion coupling that drives the
Ca2+ sensor of the exocytotic machinery (5). Given the
importance of Bcl-2 and Bcl-xL as prosurvival sentinels of
the mitochondria, combined with the indispensable func-
tion of this organelle in b-cell metabolism secretion cou-
pling, these proteins have been the targets of numerous
studies in which expression levels were manipulated with
the goal of improving islet viability. The study by Zhou et al.
(6) in 2000 was the ﬁrst to provide proof of concept that
overexpression of Bcl-xL in b cells blunted stressed-induced
apoptosis. Unexpectedly, one of the transgenic lines
expressing high levels of Bcl-xL also displayed severe hy-
perglycemia. Glucose intolerance in these animals was
linked to impaired nutrient-induced insulin secretion
caused by alterations in mitochondrial ATP generation and
intracellular Ca2+ handling (6). Substantiating this study,
Pax4-induced Bcl-xL expression in rat islets also resulted in
curtailed b-cell metabolism-secretion coupling through
blunted mitochondrial Ca2+ concentrations and decreased
ATP production (7). These early studies cautioned that Bcl-
2 protein family members might not only be involved in
regulating apoptosis but also be implicated in a day-to-day
control of cellular function. Consistent with this premise
was the elegant ﬁnding by Danial et al. (8) that Bad forms
a complex with glucokinase in order to regulate glucose-
driven mitochondrial metabolism and insulin secretion in
islets. Nonetheless, other studies have tended to argue
against the role of these proteins in glucose metabolism.
Indeed, transgenic mice either overexpressing Bcl-2 or
bearing a deletion in the BCLXL gene speciﬁcally in b cells
were not reported to display any aberrant alterations in
glucose metabolism (9,10). Thus, the relative contributions
of antiapoptotic versus alternative functions of Bcl-2 and
Bcl-xL for overall b-cell survival and performance remain
controversial.
In this issue of Diabetes, Luciani et al. (11) address this
controversy and convincingly demonstrate that Bcl-2 or
Bcl-xL dampens glucose-induced insulin secretion and
highlight the role of these prosurvival proteins as critical
physiological integrators balancing life and death with
metabolism secretion coupling in the b cell. In a ﬁrst
approach to authenticate this dual functionality, the
authors used the small-molecule antagonist compound 6
(C6) and YC137 to pharmacologically hinder Bcl-2 and
Bcl-xL. These antagonists bind to and displace proapoptotic
members such as Bad from Bcl-2 and Bcl-xL, ultimately
inducing apoptosis. In these experiments, C6 caused a rapid
disruption of the Bcl-xL/Bad complex as well as a redis-
tribution of Bax from the cytosol to mitochondria resulting
in the release of cytochrome c, activation of caspase-3, and
b-cell death. As antagonist-induced apoptosis was usually
detected 2 h posttreatment, the authors argued that cellular
events occurring within this time frame were likely in-
dependent of the central apoptotic events. In this context,
the most impressive physiological event occurring sub-
sequent to antagonistic treatment was the rapid triggering
of [Ca2+]i in cells that mimicked the effect of glucose sig-
naling. Yet, cells were cultured in the presence of low glu-
cose, suggesting increased performance of mitochondrial
metabolism leading to Ca2+ inﬂux and potentially insulin
secretion. Luciani et al. (11) methodically dissect the path-
way leading to glucose-induced insulin secretion using
various inhibitors and demonstrate that antagonizing Bcl-2/
Bcl-xL in islets recapitulates cellular events associated
with metabolism secretion coupling in b-cells: increased
ATP production causing closure of the ATP-sensitive K+
channel with the subsequent depolarization of the plasma
membrane and opening of the L-type Ca2+ channel result-
ing in submembranous increase in [Ca2+]i and ultimately
insulin exocytosis. Low glucose levels as well as a sustained
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mitochondrial proton gradient were necessary to convey the
effect of C6 and YC137. These results indicate that antag-
onist-mediated disruption of Bcl-2/Bcl-xL increases basal
glucose-driven mitochondrial metabolism. A genetic loss-of-
function approach was then used to substantiate the non-
apoptotic role of Bcl-2/Bcl-xL in metabolism secretion
coupling. Islets derived from transgenic animals bearing
either a global knockout of BCL2 or a b-cell–speciﬁc
deletion of BCLXL (BclxbKO) displayed signiﬁcant in-
creases in [Ca2+]i in response to low glucose. Nonetheless,
only Bcl-2–ablated islets exhibited precocious insulin
secretion in response to low glucose. However, glucose
tolerance was moderately improved in BclxbKO mice.
Using double transgenic animals in which both BAX
and BAK were deleted, the authors ruled out the contri-
bution of these two proapoptotic proteins in mediating
the effect of Bcl-2 and Bcl-xL in mitochondrial metabo-
lism (11).
Taken together, these data are noteworthy, as they pro-
vide the ﬁrst convincing evidence that Bcl-2 and Bcl-xL take
on dual functions in b cells: on the one hand, they are the
gatekeepers of life and death, and on the other they are the
“thermostat” of energy production in mitochondria. In fact,
we would like to propose the term “energystat” to describe
this new regulatory function of Bcl-2 and Bcl-xL. This is
particularly relevant in a cell that lacks the Pasteur effect,
a condition for being a nutrient sensor (12). In fact, these
two roles are likely not mutually exclusive, as they converge
on mitochondrial processes that will ultimately preserve b
cells from deleterious stress. Indeed, as proposed by Luciani
et al., restricting glucose metabolism may be a means by
which the nonapoptotic function of Bcl-2 and Bcl-xL protects
b cells against reactive oxygen species generated through
oxidative phosphorylation while the antiapoptotic function
preserves mitochondrial integrity under metabolic stress
conditions such as hyperglycemia. Interestingly, Bax, another
FIG. 1. Nonapoptotic function of Bcl-2 family members as energystat of mitochondrial metabolism. Through multiple interactions with mito-
chondrial proteins (cyan), antiapoptotic (yellow) as well as proapoptotic (orange) Bcl-2 family members regulate glucose-driven mitochondrial
ATP synthesis, thereby acting as energystat. Dark blue arrows depict interactions reported in the literature, while red arrows portray putative
interactions that remain to be conﬁrmed. Oxidative phosphorylation complexes are depicted as I, II, III, IV and V. ANT, adenine nucleotide
transporter; CC, citrate carrier; CS, citrate synthase; GK, glucokinase; G6P, glucose 6-phosphate; PC, pyruvate carboxylase; PDH, pyruvate de-
hydrogenase; VDAC, voltage-dependent anion channel.
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member of the Bcl-2 family, was recently linked to mito-
chondrial energy production. Indeed, BAX-deﬁcient HCT-
116 colorectal cancer cells were shown to have blunted
ATP biosynthesis, a metabolic alteration associated with
reduced citrate synthase activity. In contrast, over-
expression of Bcl-2 in wild-type HCT-116 cells caused
a drastic decrease in ATP production. The authors of this
study concluded that Bcl-2 impedes Bax action on mito-
chondrial bioenergetics by potentially blunting its
interaction with other mitochondrial proteins (13).
However, it is now clear from the study of Luciani et al.
(11) that Bcl-2 suppresses glucose-driven mitochondrial
ATP biosynthesis independently of Bax or Bak. Thus, Bcl-
2 and Bcl-xL join the armada of apoptotic factors along
with Bad and Bax that possesses dual functionality. De-
spite these ﬁndings, one outstanding question remains to
be clearly resolved from the study of Luciani et al.: what
are the downstream mitochondrial targets mediating the
nonapoptotic effects of Bcl-2 and Bcl-xL on b-cell bio-
energetics? Experimental data would tend to suggest that
the answer to this question lies within the tricarboxylic
acid (TCA) cycle and/or the oxidative phosphorylation
metabolic pathways. Indeed, 1) levels of acetyl-CoA as
well as those of citrate, a-ketoglutarate, and succinate,
three key metabolites of the TCA cycle, were reduced in
Bcl-xL-overexpressing Jurkat cells (14); 2) pyruvate, the
main substrate for the generation of mitochondrial acetyl-
CoA that fuels the TCA cycle, was unable to rescue im-
paired insulin secretion in Bcl-xL–overexpressing islets
(6); and 3) Bcl-xL was shown to interact with the ATP
synthase b-subunit and to regulate mitochondrial ener-
getics by stabilizing the inner membrane potential in
neuronal cells (15). In addition, Bax was found to interact
with citrate synthase, which is involved in the production
of citrate from acetyl-CoA and oxaloacetate (16). Thus, it
is tempting to speculate that Bcl-2 family members in-
teract with and regulate the activity of key TCA cycle
enzymes and proteins of the respiratory chain to
energystat levels of ATP biosynthesis (Fig. 1). Two po-
tential candidate targets could be the pyruvate de-
hydrogenase complex or the pyruvate carboxylase. These
control the entry of pyruvate in the form of acetyl-CoA
and oxaloacetate, respectively, into the TCA cycle. Al-
ternatively, Bcl-2 or Bcl-xL could alter levels of acetyl-
CoA by interacting with the citrate carrier, which is
responsible for the efﬂux of this metabolite from the
mitochondria to the cytosol in the form of citrate. Luciani
et al. (11) also propose that the voltage-dependent anion
channel and the mitochondrial adenine nucleotide
translocator, which are the main venues by which ATP
and ADP are exchanged between the mitochondrial ma-
trix and the cytosol, could also be targets of Bcl-2 and
Bcl-xL.
While these various targets are plausible Bcl-2 and
Bcl-xL regulatory checkpoints, several issues remain to be
addressed from the study of Luciani et al. in order to ﬁrmly
validate the bona ﬁde implication of these survival factors
in the management of mitochondrial metabolism. Indeed,
the antagonists C6 and YC137 were shown to preferentially
bind to and inhibit Bcl-2 while displaying low afﬁnity for
Bcl-xL. Consistent with the latter, islets derived from Bcl-
2–ablated transgenic mice displayed a stronger precocious
insulin secretion response to lower glucose concentrations
compared with BclxbKO islets (11). Thus, although rapid
triggering of [Ca2+]i was also observed in BclxbKO islets,
the direct impact of Bcl-xL on insulin secretion needs to be
further investigated. Furthermore, as YC137 also inhibits
Bcl-W, which is strongly expressed in islets, the role of this
prosurvival factor in regulating mitochondrial bioenergetics
needs to be addressed (17,18). This is of particular interest,
as human islets express low levels of Bcl-2 relative to other
family members such as Bcl-W (19).
In summary, the study by Luciani et al. raises serious
concerns about the feasibility of using prosurvival mem-
bers of the Bcl-2 family as therapeutic targets for the
treatment of diabetes. Indeed, human islets cultured in
high glucose were found to have reduced levels of Bcl-xL
(20). This most likely alleviates constraints on glucose-
driven mitochondrial ATP production, thereby allowing
increased insulin secretion to restore normal circulating
glucose levels. Nonetheless, decreased Bcl-xL levels also
tilt the balance between pro- and antiapoptotic factors
favoring apoptosis. Paradoxically, cell death may be in-
strumental in this context to induce b-cell renewal in order
to maintain a healthy and functional b-cell mass. Indeed,
a recent study demonstrated that insulinoma INS-1 cells
undergoing caspase-dependent apoptosis promoted the
regenerative capacity of neighboring cells by shedding
microparticles harboring the pancreatic stone protein/
regenerating protein (21). Thus, Bcl-2 protein family
members clearly act as double-edged swords in the con-
text of diabetes. Extreme care should be taken to estab-
lish whether increased or decreased expression of these
proteins would provide the most favorable outcome for
the treatment of diabetes.
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